NOTCH1 and acute lymphoblastic leukemia: The NOTCH1 signaling pathway represents an attractive target to treat T-ALL, given that NOTCH1 is activated by mutations in 65–70% of T-ALL patients [153] and is a central driver of T-ALL cell survival, growth, and metabolism [8].